Rolling admissions · Rolling admissions
BioGenerator is the startup-building and investment arm of BioSTL, a St. Louis nonprofit that has grown the region’s bioscience economy since 2004. It works through two connected engines: BioGenerator Ventures, which makes staged equity investments as companies hit technical and business milestones and syndicates deals with outside venture capital, and BioGenerator Labs, which provides shared wet-lab space in two St. Louis districts (Cortex for human health, 39 North for agtech), executive coaching, and non-dilutive Proof of Concept grants of a few thousand dollars up to $50,000. Rather than running a fixed-cohort application process, BioGenerator sources and builds companies directly, often spinning them out of Washington University in St. Louis research, and staffs them with Entrepreneurs and Executives in Residence. BioGenerator has invested more than $50 million into over 130 St. Louis startups, which have collectively raised $2.8 billion in outside capital, a 60-to-1 leverage on its own investment. BioGenerator ranks 43rd on the 2026 TIME and Statista list of America’s Best Incubators and Accelerators.
Frequency
Rolling
Duration
No fixed program length
Investment
Undisclosed — varies by stage; $50M+ invested in total since 2004
Equity
Undisclosed — staged equity investments
Program fees
None
Where
USA
Sectors
AgriTech, Biotech, Medical
Stages
Pre-Seed, Seed, Series A
Eligibility
• St. Louis-based companies, or those willing to relocate to St. Louis, often spun out of Washington University in St. Louis or other regional research institutions
• Concepts and companies sourced directly by BioGenerator’s Ventures team and Entrepreneurs/Executives in Residence, rather than through a fixed application deadline
• Rigorous due diligence applied before any investment; companies must show a credible path to raising follow-on capital from outside investors
Selection process
• Rigorous due diligence conducted before any investment decision
• Deals often syndicated with outside venture capital and other investors from the outset
• Companies that hit technical and business milestones receive staged follow-on investment, with top performers eligible for BioGenerator’s own follow-on ROI funds
Benefits
• Follow-on investment from BioGenerator’s own ROI funds for top-performing portfolio companies
• Active syndication of deals with venture capital, private equity and strategic investors across the globe
• Non-dilutive Proof of Concept grants (a few thousand dollars up to $50,000) for early de-risking work: patent review, regulatory guidance, market studies, prototyping, or lab supplies
• Coaching from Executives in Residence and BioGenerator Ventures staff throughout a company’s development
• Access to shared wet-lab space and state-of-the-art equipment at BioGenerator Labs (Cortex district for human health, 39 North for agtech)
• Hands-on support winning SBIR/STTR and other non-dilutive federal grants, with award rates significantly exceeding national averages
• Access to entrepreneurial and executive talent through the EIR and VC Fellow programs, including help building out management teams over time
• Free monthly Innovators Hour events connecting founders with the broader St. Louis bioscience community
Notable alumni
Network
Parent nonprofit BioSTL. Washington University in St. Louis, a major source of spinout companies and investment opportunities. BioGenerator Labs facilities in the Cortex and 39 North innovation districts. Syndication partners include roughly 50 representative outside investors named on BioGenerator’s Capital Attraction page, among them Novo Holdings, New Enterprise Associates (NEA), GV (Google Ventures), Menlo Ventures, Leaps by Bayer, ARCH Venture Partners, Novartis Venture Fund, Roche Venture Fund, AbbVie Ventures, Qiming Venture Partners, Sofinnova Ventures, F-Prime Capital and Atlas Venture, spanning the US, Europe and Asia.
Portfolio
130+ startups invested in since 2004; >80 currently active investments; 400+ startups supported overall including non-invested companies
Funds raised
$2.8B raised by BioGenerator portfolio companies to date
🕐 Sep 2026
Report an issue